Want to see MLYS full AI Analyst Report?
Top Page
Mineralys Therapeutics, Inc.
(NASDAQ:MLYS)
Select Model
Select Model
Rating:55Neutral
Price Target:
$27.00
▲(2.51% Upside)
Action:Reiterated
Date:08/19/26
MLYS scores as moderate: a strong strategic setup and liquidity/runway ahead of a key regulatory milestone supports the outlook, but the financial profile remains constrained by being pre-revenue with large and expanding losses and ongoing cash burn. Technical indicators add a slightly negative/neutral bias, and valuation metrics provide limited support due to negative earnings and no dividend yield provided.
Positive Factors
Clinical efficacy and biomarker differentiation
Consistent blood-pressure efficacy plus a meaningful albuminuria signal could differentiate lorundrostat in cardiorenal disease. If confirmed through regulatory review and use, the broader biological profile may support adoption beyond hypertension.
Negative Factors
Pre-revenue model and widening losses
Without product revenue, Mineralys remains dependent on successful clinical development and eventual approval to establish an operating model. Widening losses also indicate that commercialization will require substantial spending before meaningful earnings can emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy and biomarker differentiation
Consistent blood-pressure efficacy plus a meaningful albuminuria signal could differentiate lorundrostat in cardiorenal disease. If confirmed through regulatory review and use, the broader biological profile may support adoption beyond hypertension.
Read all positive factors
Mineralys Therapeutics, Inc. (MLYS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.33B
Dividend YieldN/A
Average Volume (3M)1.31M
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue GrowthN/A
EPS Growth-19.00%
CountryUS
Employees76
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.24
Shares Outstanding88,406,880
10 Day Avg. Volume629,633
30 Day Avg. Volume1,308,886
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)3.80
Price to Sales (P/S)0.00
P/FCF Ratio-17.24
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.08
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.00Price Target Upside93.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.48
Revenue Forecast (FY)N/A
Mineralys Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, o...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Mineralys does not have marketed products and therefore does not generate product sales revenue; its operations have primarily been funded through capital raising (e.g., equity financings such as its ...
Mineralys Therapeutics, Inc. Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call emphasized strong clinical data, regulatory progress toward a December 22, 2026 PDUFA, significant commercial launch preparation, and strategic actions (royalty repurchase and financing) intended to enhance long-term value and provide runway into 2028. These positive, strategic developments were tempered by materially higher near‑term expenses and a widened quarterly net loss driven largely by a one-time $200 million upfront payment and increased commercial hiring and professional fees. Management framed the elevated costs as deliberate investments to support launch readiness and future value capture.Positive Updates
Robust Clinical Efficacy and Biomarker Signals
Pivotal and follow-on data (LAUNCH-HTN, ADVANCED-HTN, Transform HTN OLE and EXPLORER-CKD) show meaningful, durable blood pressure reductions; participants with baseline albuminuria achieved a 52% placebo-adjusted reduction in urine albumin-to-creatinine ratio (UACR). Proteomic data presented at ENDO 26 demonstrated significant reductions in multiple biomarkers of heart failure risk, supporting broader biological benefits beyond BP lowering.
Negative Updates
Substantial Increase in Quarterly Net Loss
Net loss for Q2 2026 was $241.1 million versus $43.3 million in Q2 2025, an increase of approximately +457%, driven primarily by the $200.0 million upfront payment related to the royalty repurchase and increased operating expenditures.
Read all updates
Q2-2026 Updates
Positive
Negative
Robust Clinical Efficacy and Biomarker Signals
Pivotal and follow-on data (LAUNCH-HTN, ADVANCED-HTN, Transform HTN OLE and EXPLORER-CKD) show meaningful, durable blood pressure reductions; participants with baseline albuminuria achieved a 52% placebo-adjusted reduction in urine albumin-to-creatinine ratio (UACR). Proteomic data presented at ENDO 26 demonstrated significant reductions in multiple biomarkers of heart failure risk, supporting broader biological benefits beyond BP lowering.
Read all positive updates
Company Guidance
Management reiterated near‑term regulatory and commercial guidance: a December PDUFA target date (with label/post‑approval discussions expected in Oct–Nov) and plans to staff the sales organization ahead of that date to target ~50,000 high‑volume prescribers, while payer engagement already covers the vast majority of U.S. covered lives and coverage is expected to progress through 2027 (Medicare access initially via medical exception). Financially, Mineralys reported $661.4M in cash, cash equivalents and investments as of 6/30/2026 (vs. $656.6M at 12/31/2025), said this runway should fund operations including launch into 2028, closed a $200M upfront royalty repurchase (plus up to $100M in milestones; aggregate potential payments cited as up to $205M), completed a $150M equity offering and secured a $500M committed senior secured term loan; Q2 results included R&D expense of $221.4M (vs. $38.3M YOY), G&A $24.7M (vs. $8.5M), other income $5.0M (vs. $3.5M), and a net loss of $241.1M (vs. $43.3M). Clinically and commercially, they highlighted a U.S. addressable population of ~20M adults with uncontrolled/resistant hypertension, LAUNCH‑HTN/EXPLORER data showing a 52% placebo‑adjusted reduction in UACR for albuminuric patients, a lorundrostat half‑life of ~10–12 hours, and said pricing will be finalized at approval and announced at/near launch.Mineralys Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -21.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -349.54M | -154.59M | -177.77M | -71.90M | -28.12M | -19.38M |
| Net Income | -349.58M | -154.65M | -177.81M | -71.90M | -29.80M | -19.41M |
Balance Sheet | ||||||
| Total Assets | 667.85M | 661.81M | 205.90M | 251.64M | 114.44M | 11.13M |
| Cash, Cash Equivalents and Short-Term Investments | 661.41M | 656.63M | 198.19M | 236.57M | 110.11M | 10.61M |
| Total Debt | 97.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 116.94M | 15.11M | 14.65M | 10.48M | 166.71M | 34.05M |
| Stockholders Equity | 550.92M | 646.69M | 191.26M | 241.15M | -52.27M | -22.93M |
Cash Flow | ||||||
| Free Cash Flow | -138.80M | -142.43M | -166.41M | -81.17M | -29.22M | -14.56M |
| Operating Cash Flow | -138.79M | -142.42M | -166.31M | -81.17M | -29.22M | -14.56M |
| Investing Cash Flow | -484.16M | -389.75M | 114.96M | -160.47M | -21.76M | 0.00 |
| Financing Cash Flow | 659.42M | 591.00M | 116.14M | 203.25M | 128.02M | 23.81M |
Mineralys Therapeutics, Inc. Technical Analysis
Negative
26.34
Price Trends
26.77
Negative
27.29
Negative
30.20
Negative
Market Momentum
-0.28
Positive
45.56
Neutral
31.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLYS, the sentiment is Negative. The current price of 26.34 is below the 20-day moving average (MA) of 26.36, below the 50-day MA of 26.77, and below the 200-day MA of 30.20, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 45.56 is Neutral, neither overbought nor oversold. The STOCH value of 31.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLYS.
Mineralys Therapeutics, Inc. Risk Analysis
Mineralys Therapeutics, Inc. disclosed 74 risk factors in its most recent earnings report. Mineralys Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mineralys Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $3.99B | -7.38 | -94.56% | ― | ― | -203.77% | |
58 Neutral | $5.85B | -13.46 | -43.98% | ― | -100.00% | -33.88% | |
55 Neutral | $2.33B | -6.11 | -57.97% | ― | ― | -19.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $3.27B | -12.57 | -38.33% | ― | -88.87% | -35.06% |
* Healthcare Sector Average
MLYS
Mineralys Therapeutics, Inc.
26.01
10.79
70.89%
VKTX
Viking Therapeutics
33.86
6.28
22.77%
XENE
Xenon
61.93
23.33
60.44%
NAMS
NewAmsterdam Pharma Company
26.79
2.84
11.86%
Mineralys Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Mineralys Therapeutics Appoints New Chief Medical Officer
Positive
Aug 11, 2026
Mineralys Therapeutics reported second-quarter 2026 results on August 11, 2026, highlighting progress toward the potential commercialization of its hypertension drug candidate lorundrostat. The company is preparing for a possible U.S. launch, with...
Business Operations and StrategyPrivate Placements and Financing
Mineralys announces $150 million equity offering and financing
Positive
Jun 3, 2026
On June 3, 2026, Mineralys Therapeutics, Inc. priced an underwritten public offering of 5,660,378 shares of common stock at $26.50 per share, with underwriters purchasing at $25.3075 per share. Before underwriting discounts and expenses, gross pro...
Business Operations and StrategyPrivate Placements and Financing
Mineralys Secures Lorundrostat Rights and Major Financing Facility
Neutral
Jun 3, 2026
On June 2, 2026, Mineralys Therapeutics, Inc. amended its license agreement with Tanabe Pharma to secure an exclusive, worldwide, royalty-free, perpetual license to lorundrostat, eliminating future royalty and diligence obligations while retaining...
Executive/Board ChangesShareholder Meetings
Mineralys Shareholders Approve Directors and Auditor at Meeting
Positive
May 22, 2026
On May 21, 2026, Mineralys Therapeutics, Inc. held its 2026 annual meeting of stockholders, where shareholders elected three directors, Srinivas Akkaraju, Brian Taylor Slingsby and Daphne Karydas, to serve as Class III directors with terms expirin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.